Phase 1 Study of BCD-245 in Subjects With Neuroblastoma

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

BCD-245

BCD-245 is administered as prolonged intravenous infusions during each cycle

Trial Locations (3)

Unknown

RECRUITING

Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow

RECRUITING

"Russian Cancer Research Center named after N.N. Blokhin of the Ministry of Health of the Russian Federation", Moscow

RECRUITING

Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biocad

INDUSTRY